Karyopharm Therapeutics (KPTI) Stock News
$KPTI · NASDAQ · HEALTHCARE · 2 stories in 30 daysBORSA has published 2 stories on Karyopharm Therapeutics (KPTI) in the past 30 days, 1 of them high impact. BORSA’s news read on KPTI is bearish at 17/100, based on 2 company events over the past 7 days. Karyopharm Therapeutics’ next earnings report is scheduled for Monday, Nov 2.
The wire on $KPTI
newest first · updated · direct subject stories onlyKaryopharm Therapeutics resumes trading after halt.
bearish 20 · impact 50Karyopharm Therapeutics (KPTI) filed voluntary Chapter 11 petitions and entered a restructuring support agreement with lenders and noteholders. Ayrmid Ltd. will be the lead bidder in a court-supervised sale. The company secured $55M in DIP financing and expects to close the transaction in Q1 2027.
bearish 15 · impact 80The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.